NMN
Nicotinamide Mononucleotide · NAD+ Precursor
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The evidence supports one narrow, reliable claim (oral NMN raises blood NAD+) and little else with confidence. Yoshino and Klein's 2021 Science trial in 25 prediabetic postmenopausal women (250 mg/day, 10 weeks) found a real gain in skeletal-muscle insulin sensitivity, but body weight, fat mass, glucose, and lipids did not move, and the sample was tiny. Igarashi's 2022 trial in 20 older men (250 mg/day, 12 weeks) reported improved gait speed and grip, again small. Liao's 2021 four-arm trial in 48 amateur runners saw better oxygen use at ventilatory thresholds but no change in VO2max. Against these, a 2024 meta-analysis of eight RCTs (342 adults) found no significant benefit for fasting glucose, insulin, HbA1c, HOMA-IR, or lipids, though five of eight trials confirmed the NAD+ rise. So a 2 for preliminary, mixed physiological signals; the anti-aging and longevity marketing has no human outcome data behind it.
- FDA
- FDA reclassification 2022
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Long-term human safety is untested, product quality is inconsistent, and the theoretical cancer-fuel concern is unresolved; the anti-aging marketing far outruns the human evidence.
NMN is a precursor the body converts into NAD+, a molecule central to how cells make and use energy, which declines with age. It sits at the center of the modern longevity industry, and animal studies in mice have been dramatic. Human data is far thinner: several small, short placebo-controlled trials reliably show that oral NMN raises blood NAD+, and a few report modest gains in muscle insulin sensitivity, gait speed, or exercise efficiency, but a 2024 meta-analysis found no metabolic benefit overall and no study has tested whether it extends life or prevents disease. Its US legal status swung twice, with the FDA excluding it as a supplement in 2022 before reversing course in September 2025. The honest headline is a molecule that does one measurable thing in people, with an anti-aging reputation the human evidence has not yet earned.
The flagship longevity supplement of the 2020s, and the most commercially conflicted.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Nicotinamide mononucleotide (NMN) is a nucleotide derivative, chemically beta-nicotinamide D-ribose-5-phosphate, that serves as direct precursor to nicotinamide adenine dinucleotide (NAD+) through the salvage pathway of NAD+ biosynthesis. NAD+ is one of the most abundant and metabolically central cofactors in human biology, required for over 500 enzymatic reactions including oxidative phosphorylation (electron transfer in mitochondrial complex I as NADH), sirtuin deacetylation (NAD+ consumed as cofactor for SIRT1-7 longevity-associated enzymes), PARP DNA damage repair, CD38 immune signaling, and broader cellular energy metabolism. Cellular NAD+ levels decline substantially with aging, the foundational observation that drives the substantial longevity supplementation framework around NAD+ precursor supplementation (NMN, NR/nicotinamide riboside, and broader NAD+ pathway interventions). The substantial NAD+ decline biology was characterized substantially through the 1990s-2010s with David Sinclair (Harvard), Leonard Guarente (MIT), Charles Brenner (City of Hope, NR pioneer), Shin-ichiro Imai (Washington University in St. Louis, NMN/NAD+ research leader), and various other substantial researchers establishing the foundational framework. The pharmacological mechanism centers on NAD+ replenishment through the substantial salvage pathway. The substantial NAD+ biosynthesis includes three pathways: (1) de novo synthesis from tryptophan through the kynurenine pathway (substantial but slow); (2) Preiss-Handler pathway from nicotinic acid (niacin, vitamin B3); (3) salvage pathway from nicotinamide (the substantial dominant pathway in most cells). NMN enters the salvage pathway directly, converted to NAD+ through the NMNAT enzyme family (NMNAT1-3) with substantial tissue-specific expression. NR (nicotinamide riboside, the substantial alternative NAD+ precursor) requires substantial NRK1/NRK2 phosphorylation to NMN before NAD+ synthesis, providing substantial mechanism distinction between NMN and NR supplementation despite substantial overlapping NAD+ replenishment endpoints. The substantial Sinclair longevity framework substantially shaped modern consumer NMN positioning. David Sinclair's substantial Harvard research investment, substantial Lifespan: Why We Age, And Why We Don't Have To 2019 book, substantial podcast presence, and substantial commercial connections (MetroBiotech NMN pharmaceutical development, various supplement company associations) substantially drove consumer market expansion through the 2019-2024 period. The substantial Sinclair framework integrates substantial sirtuin activation hypothesis (substantial Howitz 2003 SIRT1 framework with substantial Pacholec 2010 mechanism recalibration challenges) with substantial NAD+ precursor supplementation framework. The substantial Bryan Johnson Blueprint protocol prominent NMN inclusion (1g/day) further substantially shaped consumer positioning. The substantial mainstream gerontology community is substantially more cautious than Sinclair consumer-facing communications suggest about the strength of human longevity translation evidence; the substantial commercial interests influence substantial public communication framework. The substantial Yoshino 2021 Science human clinical trial provided foundational metabolic evidence. The substantial trial in postmenopausal prediabetic women (250mg/day NMN x 10 weeks) demonstrated substantial improvements in insulin sensitivity in muscle and modest improvements in metabolic markers. Subsequent work (Igarashi 2022 Nature comprehensive metabolomic characterization, Liao 2021 Sci Adv exercise framework, Yamane 2023 healthy adults framework, various others) has substantially extended the metabolic evidence base while substantial longevity-specific clinical outcome evidence remains preliminary. The substantial NAD+ blood level elevation evidence is consistent across NMN supplementation trials; whether NAD+ blood level elevation translates to substantial tissue NAD+ elevation and substantial clinical longevity outcomes remains substantial preliminary evidence-translation question. The substantial FDA regulatory whiplash represents among the substantially clearest M-05 Regulatory whiplash examples in modern consumer supplementation. The substantial NMN had operated as dietary supplement under DSHEA framework through 2017-2022. The substantial October 2022 FDA letter to Inner Mongolia Kingdomway Pharmaceutical (NMN supplier) indicated that NMN had been "authorized for investigation as a new drug" prior to substantial supplement marketing under DSHEA, substantially excluding NMN from dietary supplement category under DSHEA Section 201(ff)(3)(B). The substantial subsequent enforcement uncertainty, substantial supplement industry response, substantial Congressional engagement, and substantial ongoing regulatory development through 2023-2024 created substantial commercial uncertainty. The substantial situation continues to evolve with substantial FDA enforcement discretion, substantial supplement industry advocacy, and substantial pharmaceutical company NMN drug development (MetroBiotech MIB-626 pharmaceutical NMN clinical development). The substantial regulatory complexity substantially distinguishes NMN from substantial NR (nicotinamide riboside, ChromaDex Niagen) which maintains substantial DSHEA dietary supplement status without parallel regulatory complications.
How it is taken
Standard NMN supplementation centers on 250-1000mg/day across general supplementation and clinical applications. The Yoshino 2021 Science postmenopausal prediabetic protocol used 250mg/day; the Liao 2021 Sci Adv athletic protocol used 300-1200mg/day dose-dependent; the Yamane 2023 healthy older adult protocol used 250mg/day; the Bryan Johnson Blueprint protocol uses 1g/day. The dose-response relationship appears reasonably linear within the 250-1000mg/day range; higher doses (>1500mg/day) produce diminishing returns and theoretical concerns. Take in the morning with or without food, first-thing-morning timing reflects circadian NAD+ pathway considerations and substantial commercial positioning emphasis; specific food considerations are modest. The substantial NMN bioavailability through oral administration is reasonable through the substantial intestinal absorption framework, substantially better than substantial resveratrol bioavailability gap (<1% systemic). The substantial sublingual NMN delivery may provide modest bioavailability advantage by bypassing first-pass hepatic metabolism; substantial preliminary evidence. The substantial liposomal NMN formulations provide additional bioavailability enhancement at substantial premium pricing. Treatment durations matter substantially, Yoshino 2021 used 10 weeks for insulin sensitivity outcomes; Yamane 2023 used 12 weeks for physical performance outcomes; longevity applications imply chronic dosing across years. The substantial Upper Limit (UL) has not been formally established; chronic doses above 1500mg/day produce theoretical concerns about NAD+ pathway saturation, theoretical NADP/NADPH imbalance, and substantial commercial considerations of diminishing returns at higher doses. The substantial form selection from NMN category: pharmaceutical-grade powder (>99% purity) preferred for clinical applications; sublingual tablets for bioavailability optimization; liposomal formulations for premium positioning; NMN+pterostilbene combinations following Sinclair framework; NR (nicotinamide riboside) as substantial alternative NAD+ precursor with substantially clearer regulatory status under DSHEA. The substantial FDA regulatory complexity affects substantial US consumer market access, substantial enforcement uncertainty through 2023-2024 created substantial commercial complexity. The substantial pregnancy avoidance is precautionary given limited safety data. The substantial drug interaction profile is modestly characterized; coordinate with prescribing physicians for users on multiple medications. The substantial mainstream geriatric medicine integration remains limited despite substantial Sinclair-aligned consumer positioning; reasonable consumer guidance: NMN is substantively credible NAD+ precursor with substantial mechanism evidence and substantial preliminary human clinical evidence; not established longevity intervention with documented lifespan outcomes; substantial regulatory complexity affects supplement category positioning.
- Standard supplementation
- 250-1000mg NMN daily
- Yoshino 2021 postmenopausal protocol
- 250mg/day x 10 weeks
- Liao 2021 athletic dose-response
- 300-1200mg/day (dose-dependent)
- Yamane 2023 healthy older adults
- 250mg/day x 12 weeks
- Bryan Johnson Blueprint
- 1g/day
- Premium longevity stack range
- 500-1000mg/day
- Take with
- Morning, with or without food
- Treatment duration for clinical effects
- 10-12+ weeks
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
NMN Pharmaceutical-Grade Powder (>99% Purity)
Pharmaceutical-grade NMN powder typically standardized to >99% purity verified through HPLC. Substantial Japanese manufacturers (Mirai Lab, Effepharm) and Chinese manufacturers provide pharmaceutical-grade supply. Major reputable supplement brands (Renue by Science, Double Wood Supplements, ProHealth Longevity, Life Extension) provide pharmaceutical-grade NMN products. The substantial FDA regulatory complexity affects substantial US consumer market access; substantial Asian and European market continues.
NMN Sublingual Tablets / Fast-Dissolve
Sublingual NMN delivery designed for absorption through oral mucosa, bypassing first-pass hepatic metabolism. Substantial preliminary bioavailability advantage; clinical evidence comparison to oral capsules remains preliminary. Available from various premium supplement manufacturers.
NMN Liposomal Formulations
Liposomal NMN delivery designed for substantial absorption enhancement through lipid vesicle encapsulation. Substantial preliminary bioavailability evidence; substantial premium pricing. Available from various premium supplement manufacturers including Renue by Science.
MetroBiotech MIB-626 Pharmaceutical NMN
MetroBiotech (David Sinclair commercial association) pharmaceutical NMN clinical development, Phase 1, Phase 2 trials. Pharmaceutical-grade development distinct from consumer supplement positioning. Not commercially available as consumer product; pharmaceutical development trajectory continues.
NMN + Pterostilbene Combinations
Premium longevity supplement combination, NMN provides NAD+ substrate; pterostilbene provides substantial sirtuin pathway modulation (methylated resveratrol analog with substantial bioavailability advantage over free resveratrol). Mechanistically reasonable comprehensive longevity supplementation following Sinclair framework. Common in premium longevity brands including Renue by Science and various others.
NMN + Resveratrol Combinations
Common longevity supplement combination following Sinclair framework, NMN provides NAD+ substrate; resveratrol provides substantial sirtuin pathway modulation despite substantial bioavailability limitations. Mechanistically reasonable but substantial resveratrol bioavailability concern (<1% free systemic).
NR (Nicotinamide Riboside) Alternative, Niagen by ChromaDex
Alternative NAD+ precursor through different pathway, NR requires NRK1/NRK2 phosphorylation to NMN before NAD+ synthesis. ChromaDex Niagen substantial commercial brand heritage; pharmacology overlapping with NMN but mechanism distinct. The substantial ChromaDex/Elysium Health commercial positioning and substantial regulatory status (NR maintains substantial DSHEA dietary supplement status without NMN-equivalent regulatory complications) provide substantial alternative framework.
NMN-Containing Comprehensive Longevity Stacks
NMN commonly included in comprehensive longevity stack formulations alongside resveratrol, pterostilbene, quercetin, CoQ10, and various other longevity supplements. Mechanistically reasonable comprehensive support; verify NMN dose specifically. Bryan Johnson Blueprint protocol prominent inclusion.
Niacin (Nicotinic Acid) / Niacinamide (Nicotinamide) Alternative
Alternative NAD+ precursors through Preiss-Handler pathway (nicotinic acid) and salvage pathway (nicotinamide). Substantially lower cost than NMN or NR; substantially smaller longevity-specific clinical research investment. Reasonable cost-effective alternative for users seeking NAD+ pathway support without premium longevity positioning.
Who it works for, and who it does not
Healthy adults seeking longevity supplementation
Substantial Sinclair longevity framework and Bryan Johnson Blueprint protocol prominent NMN inclusion drive substantial consumer interest. Clinical evidence for longevity outcomes in healthy users remains preliminary; substantial mechanism credibility through NAD+ replenishment. Reasonable component of comprehensive longevity nutrition for users prioritizing this approach; not established intervention with documented lifespan outcomes.
Older adults with age-related metabolic decline
Yoshino 2021 Science postmenopausal prediabetic evidence and Yamane 2023 healthy older adult evidence support modest metabolic benefits at 250mg/day. Reasonable adjunct to comprehensive metabolic management. Coordinate with primary care or endocrinology.
Athletic performance and exercise adaptation
Liao 2021 Sci Adv athletic performance evidence supports modest aerobic capacity improvements at 300-1200mg/day in amateur runners. Reasonable component of comprehensive athletic supplementation; dose-dependent effects per Liao framework.
Postmenopausal women (insulin sensitivity)
Yoshino 2021 Science foundational evidence specifically in postmenopausal prediabetic women supports muscle insulin sensitivity improvements. Reasonable component of comprehensive postmenopausal metabolic management.
Neurodegenerative disease (preliminary research)
Substantial preliminary evidence for NAD+ replenishment in neurodegenerative disease applications (Brakedal 2022 NR Parkinson's, various preliminary NMN research). Research-grade specialist applications; not established clinical intervention for neurodegenerative disease. Specialist neurology coordination.
Pregnancy and lactation
Limited pregnancy and lactation safety data for NMN supplementation. Generally avoid systemic supplementation in pregnancy and lactation; coordinate with OB-GYN.
Active cancer or cancer history
Theoretical concern about NAD+ replenishment supporting tumor metabolism, substantial preclinical evidence is mixed (some tumors require substantial NAD+ for proliferation; NAD+ replenishment may support normal tissue resilience). Coordinate with oncology; benefit-risk assessment essential.
Pediatric use
Limited pediatric safety data; not appropriate for routine pediatric supplementation.
Mainstream geriatric / longevity medicine integration
Mainstream geriatric medicine and gerontology professional societies have not integrated NMN into standard care guidelines despite substantial Sinclair consumer positioning. The mainstream clinical guideline framework remains substantially more cautious than substantial Sinclair-aligned consumer communications suggest.
Type 2 diabetes (preliminary)
Yoshino 2021 prediabetic evidence and preliminary T2DM applications support modest glycemic effects. Effect sizes substantially smaller than established diabetes medications; reasonable adjunct under endocrinology coordination.
Cardiovascular disease (preliminary)
Substantial preliminary preclinical evidence for cardiovascular applications through NAD+ replenishment and SIRT pathway support. Human clinical evidence remains preliminary; reasonable component of comprehensive cardiovascular nutrition under cardiology coordination.
Users on multiple medications
Limited drug interaction characterization for NMN; theoretical interactions through NAD+/sirtuin/PARP pathway modulation. Coordinate with prescribing physicians for users on multiple medications.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
Pterostilbene
Premium longevity supplement combination following Sinclair framework, NMN provides NAD+ substrate; pterostilbene provides substantial sirtuin pathway modulation (methylated resveratrol analog with substantial bioavailability advantage). Mechanistically reasonable comprehensive longevity supplementation. Common in premium longevity brands.
Resveratrol
Common longevity supplement combination following Sinclair framework. NMN provides NAD+ substrate; resveratrol provides sirtuin pathway modulation despite bioavailability limitations (<1% free systemic). Mechanistically reasonable framework; clinical evidence for combination effects beyond individual components preliminary.
NR (Nicotinamide Riboside)
Alternative NAD+ precursor through different pathway, combining NMN and NR is mechanistically redundant rather than synergistic. Reasonable to choose between NMN and NR based on substantial regulatory considerations, substantial pricing, and substantial individual preference rather than combining.
CoQ10
Common longevity and cardiovascular combination, CoQ10 provides mitochondrial electron transport support; NMN provides NAD+ substrate. Mechanistically complementary at the mitochondrial level. Common in comprehensive longevity formulations.
Quercetin (Senolytic Framework)
Common longevity combination integrating NAD+ pathway support (NMN) with senolytic mechanism (quercetin from Kirkland Mayo Clinic D+Q research framework). Mechanistically reasonable comprehensive aging biology framework.
Spermidine
Common longevity combination integrating NAD+ pathway (NMN) with autophagy framework (spermidine). Mechanistically complementary aging biology approach. Common in premium longevity stacks.
Niacin / Niacinamide
Alternative NAD+ precursors, niacin (nicotinic acid) and niacinamide (nicotinamide) provide substantial cost-effective NAD+ pathway support but through different pathway entry points. Combining NMN with substantial niacin supplementation is mechanistically redundant. Reasonable to choose based on cost and clinical positioning preferences.
Pregnancy
Limited pregnancy safety data; generally avoid systemic NMN supplementation in pregnancy.
Active Cancer or Cancer History
Theoretical concern about NAD+ replenishment supporting tumor metabolism. Coordinate with oncology; substantial preclinical evidence is mixed.
Pediatric Use
No pediatric safety data; not appropriate for routine pediatric supplementation.
PARP Inhibitor Cancer Medications
Theoretical NAD+/PARP pathway interaction. Specialist oncology coordination essential for users on PARP inhibitor chemotherapy (olaparib, niraparib, rucaparib, talazoparib).
CD38 Modulation Research
CD38 is substantial NADase consuming NAD+ at substantial rates; CD38 inhibition is substantial research framework for NAD+ replenishment. Specialist research coordination if combined applications considered.
What to look for on the label
Look for: pharmaceutical-grade NMN with >99% purity verified through HPLC; explicit mg NMN content per serving; reputable manufacturer with quality control disclosure; third-party testing including heavy metal verification given substantial Asian manufacturing supply chain; substantial brand positioning with substantial quality verification framework. Avoid: products without explicit NMN purity disclosure (likely standardization compromise); very low-cost NMN products (likely quality compromise); aggressive marketing claims about lifespan extension or "anti-aging" that substantially exceed evidence base; products from manufacturers without third-party testing or heavy metal verification; proprietary "longevity blends" obscuring NMN dose specifically.
Safety in detail
- Generally well-tolerated at typical supplementation doses (250-1000mg/day) based on substantial Yoshino 2021, Liao 2021, Yamane 2023, and other clinical trial follow-up.
- GI effects (mild nausea, abdominal discomfort) possible at higher doses; typically dose-related and resolves with dose reduction or food administration.
- Theoretical concerns about NAD+ pathway saturation at chronic very high doses (>1500mg/day) including theoretical NADP/NADPH imbalance and theoretical methyl group depletion through nicotinamide methylation (NNMT enzyme).
- Theoretical concerns about NAD+ replenishment supporting tumor metabolism, substantial preclinical evidence is mixed; some tumors require substantial NAD+ for proliferation while NAD+ replenishment may support normal tissue resilience. Coordinate with oncology for users with active cancer or significant cancer history.
- Drug interaction profile is modestly characterized, theoretical interactions through NAD+/sirtuin/PARP pathway modulation; specific clinical interactions not well-established at typical supplementation doses.
- Pregnancy and lactation: limited safety data; generally avoid by precautionary principle.
- Pediatric use: no pediatric safety data; not appropriate for routine pediatric supplementation.
- The substantial FDA regulatory complexity through 2022-2024 has created substantial commercial uncertainty in US market, substantial consumer access through Asian and European markets continues; substantial US market continues with enforcement discretion uncertainty.
- Quality variation across consumer supplements is substantial, purity verification (>99% NMN by HPLC) matters substantially; heavy metal testing important given substantial Asian manufacturing supply chain; reputable manufacturers with third-party testing address these concerns.
- Long-term safety record at standard supplementation doses appears reasonable based on substantial Asian consumer use and accumulating Western clinical trial follow-up; rigorous long-term safety data (>5 years) limited.
- The substantial Sinclair-aligned consumer marketing creates substantial inappropriate positioning concern about lifespan extension claims that substantially exceed current clinical evidence base.
What people get wrong
Often saidNMN extends human lifespan.
ActuallyIt does not, at least, the human longevity translation evidence is substantially more preliminary than substantial Sinclair-aligned consumer positioning suggests. Substantial mouse longevity evidence (Mills 2016) and substantial preliminary human metabolic evidence (Yoshino 2021, Liao 2021, Yamane 2023) provide substantial mechanism credibility; substantial lifespan or healthspan extension claims in humans substantially exceed current clinical evidence base. The longevity framework is research-grade interest rather than established human intervention.
Often saidNMN is the same as NR.
ActuallySubstantively distinct, NMN and NR are substantial alternative NAD+ precursors through substantial different pathway entry points. NR requires substantial NRK1/NRK2 phosphorylation to NMN before NAD+ synthesis; NMN enters salvage pathway directly. Substantial overlapping NAD+ endpoint outcomes but substantial mechanism distinction. Substantial regulatory clarity advantage for NR through DSHEA; substantial regulatory complexity for NMN through FDA 2022 letter. Substantial individual choice considerations.
Often saidHigher NMN doses produce proportionally better outcomes.
ActuallyDiminishing returns. The substantial Yoshino 2021 protocol used 250mg/day; substantial Liao 2021 athletic protocol used 300-1200mg/day with dose-dependent effects in athletic context. Bryan Johnson Blueprint uses 1g/day. Doses above 1500mg/day produce diminishing returns with theoretical NAD+ pathway saturation considerations. Reasonable supplementation should stay within 250-1000mg/day range.
Often saidNMN supplementation is fully approved by FDA.
ActuallyIt is not, substantial FDA October 2022 letter indicated NMN had been "authorized for investigation as a new drug" prior to substantial supplement marketing under DSHEA, substantially excluding NMN from dietary supplement category under DSHEA Section 201(ff)(3)(B). Substantial enforcement uncertainty continues; substantial consumer market continues through substantial enforcement discretion. Substantial regulatory complexity affects substantial supplement category positioning.
Often saidNMN is safe at any dose because it's a natural compound.
ActuallyTheoretical concerns at chronic very high doses include NAD+ pathway saturation, NADP/NADPH imbalance, and methyl group depletion through nicotinamide methylation. Theoretical concerns about NAD+ replenishment supporting tumor metabolism in cancer contexts. Substantial pregnancy and pediatric avoidance through limited safety data. The "natural therefore safe at any dose" framing applies poorly to bioactive compounds with substantial pharmacological effects.
Often saidNMN supplementation is a substitute for a healthy lifestyle.
ActuallyIt is not. Substantial mechanism credibility through NAD+ replenishment provides reasonable adjunct to comprehensive healthy aging framework including substantial dietary intake, substantial exercise, substantial sleep, substantial stress management, substantial social engagement, substantial purpose, substantial medical preventive care. The substantial Sinclair-aligned framework substantially emphasizes broader lifestyle framework alongside supplementation; substantial supplementation alone does not provide established longevity outcomes.
Often saidNMN and resveratrol must be combined for longevity effects.
ActuallyThe substantial Sinclair-aligned framework substantially emphasizes combination supplementation, but substantial clinical evidence for combination effects beyond individual components remains preliminary. Substantial mechanism rationale (NMN provides NAD+ substrate; resveratrol provides sirtuin pathway modulation) is reasonable; substantial individual component evidence is substantial; substantial combination-specific evidence is preliminary. Reasonable individual choice rather than required combination.
Who profits, and who pushes back
Mainstream gerontology longevity framework caution
Despite substantial Sinclair-aligned consumer positioning and substantial preliminary human clinical evidence (Yoshino 2021, Liao 2021, Yamane 2023), the substantial mainstream gerontology community is substantially more cautious about the strength of human longevity translation evidence. The substantial mouse longevity evidence (Mills 2016 and various others) does not directly translate to substantial human longevity outcomes; substantial human studies have demonstrated substantial NAD+ blood level elevation and modest metabolic improvements rather than substantial lifespan or healthspan extension evidence. Reasonable position: NMN provides substantial mechanism credibility through NAD+ replenishment with substantial preliminary metabolic clinical evidence; substantial lifespan or healthspan extension claims substantially exceed current human clinical evidence base; reasonable component of comprehensive longevity nutrition for users prioritizing this approach; not established intervention with documented longevity outcomes in humans.
FDA regulatory complexity vs consumer market continuation
The substantial FDA October 2022 letter to Inner Mongolia Kingdomway indicating NMN had been "authorized for investigation as a new drug" substantially excluded NMN from dietary supplement category under DSHEA Section 201(ff)(3)(B). The substantial subsequent enforcement uncertainty through 2023-2024 creates substantial commercial complexity. The substantial supplement industry continues substantial NMN marketing through substantial enforcement discretion uncertainty; substantial Asian and European markets continue substantial NMN availability without parallel regulatory complications. The substantial NR alternative through ChromaDex maintains substantial DSHEA dietary supplement status. Reasonable position: substantial regulatory complexity continues; substantial consumer access continues with substantial uncertainty; users prioritizing substantial regulatory clarity may prefer NR alternative; users prioritizing substantial NMN-specific mechanism evidence may continue NMN supplementation with substantial commercial uncertainty awareness.
Shin-ichiro Imai
Substantial foundational NMN biosynthesis pathway and NAD+ aging biology research investment. Independent academic with substantial subsequent commercial associations through scientific advisory roles.
David Sinclair
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Substantial Harvard academic position. Substantial commercial associations including MetroBiotech pharmaceutical NMN development. Substantial Lifespan book, podcast presence, and broader consumer longevity supplementation positioning. Mixed independence with substantial commercial influence disclosed.
Charles Brenner
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Substantial foundational NR (nicotinamide riboside) research investment. Substantial ChromaDex commercial scientific advisory associations. Substantial parallel NAD+ precursor framework. Disclosed commercial relationships.
Bryan Johnson
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Substantial public promotion of NMN at 1g/day as part of Blueprint longevity protocol. Direct-to-consumer Blueprint supplement company substantial commercial interest. Disclosed commercial context.
MetroBiotech
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Substantial pharmaceutical NMN clinical development through MIB-626 Phase 1, Phase 2 trials. Substantial Sinclair commercial association. Substantial pharmaceutical category positioning distinct from consumer supplement positioning. Disclosed industry context.
ChromaDex
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Substantial NR (nicotinamide riboside) commercial framework through Niagen brand. Substantial DSHEA regulatory clarity advantage versus substantial NMN regulatory complexity. Disclosed industry context.
FDA
Substantial October 2022 letter to Inner Mongolia Kingdomway substantially excluding NMN from dietary supplement category under DSHEA. Substantial M-05 Regulatory whiplash foundational regulatory action. Substantial enforcement discretion uncertainty continues through 2023-2024.
Renue by Science, Double Wood Supplements, ProHealth Longevity
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Substantial commercial interests in NMN consumer supplement category. Substantial premium positioning frameworks. Disclosed industry context.
How we got here
NMN's history traces to substantial NAD+ pathway research investment through the mid-20th century. The substantial NAD+ cofactor biology characterization developed substantially through 1930s-1970s with substantial niacin (vitamin B3) discovery, substantial NAD+ enzymatic role characterization, and substantial broader NAD+ pathway biology framework. The substantial NAD+ decline-with-aging biology emerged substantially through 1990s-2000s academic research. The substantial Shin-ichiro Imai research investment at Washington University in St. Louis substantially established the modern NMN longevity framework. Imai's substantial work characterizing NMN biosynthesis pathway biology, NAD+ decline with aging, and NAD+ replenishment therapeutic potential substantially drove subsequent NMN therapeutic positioning. The substantial Charles Brenner research investment characterizing NR (nicotinamide riboside) pathway provided substantial parallel framework. The substantial mouse preclinical era developed substantially through the 2010s. The substantial Mills 2016 Cell Metabolism mouse NMN supplementation longevity research demonstrated substantial improvements in age-related physiological decline. Various other substantial preclinical investigations provided substantial mechanism framework supporting subsequent human clinical research investment. The substantial Sinclair consumer positioning era began substantially with David Sinclair's substantial Harvard research, substantial Lifespan: Why We Age, And Why We Don't Have To 2019 book, substantial podcast presence (Joe Rogan, Lex Fridman, Andrew Huberman, various others), and substantial commercial connections (MetroBiotech pharmaceutical NMN development, various supplement company associations). The substantial Sinclair framework substantially drove substantial consumer market expansion through 2019-2024. The substantial mainstream gerontology community has been substantially more cautious than Sinclair consumer communications suggest about the strength of human longevity translation evidence. The substantial Yoshino 2021 Science human clinical trial provided substantial foundational metabolic evidence, 250mg/day NMN x 10 weeks in postmenopausal prediabetic women demonstrating substantial muscle insulin sensitivity improvements. The substantial Liao 2021 Sci Adv Chinese athletic performance RCT demonstrating dose-dependent aerobic capacity improvements provided substantial additional human evidence. The substantial Yamane 2023 Cell Rep Med Japanese healthy older adults RCT extended healthy population evidence. The substantial MetroBiotech MIB-626 pharmaceutical NMN clinical development era began substantially with substantial David Sinclair commercial association. Phase 1, Phase 2 trials through 2021-2024 represent substantial pharmaceutical category development. The substantial pharmaceutical positioning substantially relates to the substantial FDA regulatory complexity affecting NMN supplement category. The substantial FDA regulatory whiplash era developed substantially in October 2022 with substantial FDA letter to Inner Mongolia Kingdomway Pharmaceutical indicating NMN had been "authorized for investigation as a new drug" prior to substantial supplement marketing under DSHEA, substantially excluding NMN from dietary supplement category under DSHEA Section 201(ff)(3)(B). The substantial subsequent enforcement uncertainty through 2023-2024 created substantial commercial complexity. The substantial supplement industry response included substantial advocacy through Congressional engagement, substantial trade association response, and substantial product reformulation considerations. The substantial NR alternative through substantial ChromaDex commercial framework continued substantial supplement market positioning without parallel regulatory complications. The substantial Bryan Johnson Blueprint protocol prominent inclusion (1g/day NMN) through 2022-2024 further substantially shaped substantial consumer positioning. The substantial broader longevity supplementation framework including resveratrol, pterostilbene, NMN, quercetin, spermidine, and various other compounds matured substantially through this period. The substantial modern consumer market continues substantial growth through 2024 despite substantial regulatory complexity. The substantial mechanism credibility (NAD+ replenishment through salvage pathway), the substantial preliminary clinical evidence (Yoshino 2021, Liao 2021, Yamane 2023), and the substantial mainstream gerontology cautious framework characterize the substantial complexity of the modern NMN positioning.
- 1930s-1970sNAD+ cofactor biology foundational characterization
- 1990s-2000sNAD+ decline with aging biology emergence
- 2000s-2010sImai NMN/NAD+ research at Washington University in St. Louis
- 2014Imai Cell foundational NAD+ aging biology
- 2016Mills Cell Metab mouse NMN longevity preclinical foundational
- 2016Trammell Nat Commun NR pharmacokinetic foundational (parallel pathway)
- 2019Sinclair Lifespan book popularizes longevity supplementation
- 2020Irie Endocr J Japanese NMN safety/pharmacokinetic foundational
- 2021Yoshino Science postmenopausal prediabetic foundational; Liao Sci Adv athletic performance
- 2021-2024MetroBiotech MIB-626 pharmaceutical NMN clinical development
- 2022Igarashi Nature metabolomic comprehensive characterization
- 2022 (October)FDA letter to Inner Mongolia Kingdomway, substantial M-05 regulatory whiplash foundational event
- 2022-2024Substantial FDA regulatory enforcement uncertainty
- 2023Yamane Cell Rep Med healthy older adults RCT
- 2022-2024Bryan Johnson Blueprint protocol prominent NMN inclusion
- 2024Substantial regulatory development continues
What we do not know
- Whether the substantial FDA regulatory complexity will resolve toward substantial DSHEA dietary supplement framework continuation or substantial pharmaceutical category transition, substantial commercial uncertainty continues through 2024.
- Whether the substantial MetroBiotech MIB-626 pharmaceutical NMN clinical development will mature into substantial pharmaceutical FDA approval, substantial commercial trajectory continues.
- Whether the substantial Sinclair longevity framework consumer positioning will mature into evidence-based clinical applications or remain substantial consumer wellness positioning beyond rigorous clinical evidence base.
- Whether genetic variants affecting NAD+ pathway enzymes produce substantial individual variability in NMN clinical response.
- Whether tissue-level NAD+ elevation translates from substantial blood NAD+ elevation evidence, substantial mechanism-translation question remains preliminary.
- Whether the substantial mainstream geriatric medicine integration will mature beyond limited current integration despite substantial Sinclair-aligned consumer positioning.
- Whether NMN provides substantial clinical advantages over substantial NR (nicotinamide riboside), substantial mechanism distinction (different pathway entry points) with substantial overlapping NAD+ endpoint outcomes; substantial regulatory clarity advantage for NR.
- Whether the substantial preliminary longevity evidence (Yoshino 2021, Liao 2021, Yamane 2023) will mature into substantial outcome trials demonstrating substantial lifespan or healthspan extension in humans.
- How the substantial NAD+/PARP/sirtuin/CD38 broader pathway research will inform substantial integrated NAD+ pathway interventions beyond NMN supplementation alone.
- Whether the substantial "Nature's anti-aging molecule" consumer positioning will face substantial regulatory pressure or mature into appropriate evidence-based consumer guidance.
Legal status
Substantial regulatory complexity in US market through FDA October 2022 letter framework. NMN had operated as dietary supplement under DSHEA framework through 2017-2022. Substantial subsequent enforcement uncertainty, substantial supplement industry response, and substantial ongoing regulatory development through 2023-2024 created substantial commercial uncertainty. Substantial Asian (Japan particularly) and European markets continue substantial NMN supplement availability without parallel regulatory complications. The substantial NR (nicotinamide riboside) alternative maintains substantial DSHEA dietary supplement status without NMN-equivalent regulatory complications through substantial ChromaDex commercial framework. Major retail NMN supplement brands include Renue by Science (substantial premium positioning), Double Wood Supplements (substantial mass-market positioning), ProHealth Longevity, Life Extension, NOW Foods, Doctor's Best, and various others. Premium sublingual and liposomal formulations command substantial premium pricing. The substantial MetroBiotech (David Sinclair commercial association) pharmaceutical NMN clinical development (MIB-626) represents pharmaceutical category positioning distinct from consumer supplement positioning. Production sourcing is concentrated in Asian (Japan, China) manufacturing, Mirai Lab (Japan), Effepharm (China), Inner Mongolia Kingdomway Pharmaceutical (China, recipient of FDA October 2022 letter), and various other manufacturers. Quality variation is substantial, purity verification (>99% NMN by HPLC), heavy metal testing (substantial concern given Asian manufacturing), and third-party verification matter substantially. Substantial premium brands provide substantial quality verification framework; substantial mass-market alternatives may have substantial quality variation. The substantial Sinclair longevity framework continues to drive substantial consumer market interest despite substantial regulatory complexity; the substantial Bryan Johnson Blueprint protocol prominent inclusion further drives substantial consumer market positioning. The substantial mainstream geriatric medicine integration remains limited; substantial functional medicine and longevity medicine community has substantial integration despite limited mainstream clinical guideline integration.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
NMN sourcing is concentrated in substantial Asian (Japan, China) manufacturing infrastructure. Substantial Japanese manufacturers include Mirai Lab and Effepharm with substantial pharmaceutical-grade NMN production. Substantial Chinese manufacturers include Inner Mongolia Kingdomway Pharmaceutical (substantial recipient of FDA October 2022 regulatory letter), GeneHarbor, and various other manufacturers. Production involves substantial pharmaceutical-grade chemistry through enzymatic synthesis or chemical synthesis pathways. Quality variation across consumer supplements is substantial, purity verification (>99% NMN by HPLC) matters substantially; heavy metal testing is substantial concern given Asian manufacturing supply chain considerations; third-party verification through USP, NSF, ConsumerLab provides standard quality assurance framework. The substantial commercial supply chain has matured substantially through 2017-2024 with substantial commercial production capacity expansion. The substantial FDA regulatory complexity through October 2022 letter affected substantial supply chain considerations, substantial commercial framework continues with substantial enforcement discretion. The substantial Asian and European supplement market continues substantial production capacity; the substantial US market continues with substantial commercial uncertainty. Premium brands (Renue by Science, ProHealth Longevity, others) provide substantial quality verification framework; substantial mass-market alternatives (Double Wood Supplements, various others) provide substantial cost-effective positioning at substantially smaller quality verification frameworks. The substantial pharmaceutical-grade MetroBiotech MIB-626 manufacturing represents substantial pharmaceutical category framework distinct from consumer supplement supply chain. The substantial pricing variation reflects manufacturing quality, brand positioning, and formulation complexity (sublingual, liposomal command substantial premium pricing). The substantial NR (nicotinamide riboside) alternative through substantial ChromaDex commercial framework provides substantial alternative NAD+ precursor supply with substantial regulatory clarity.
At a glance
- Class
- NAD+ precursor (salvage pathway)
- Chemical structure
- Beta-nicotinamide D-ribose-5-phosphate
- Standard supplementation
- 250-1000mg NMN daily
- Yoshino 2021 protocol
- 250mg/day x 10 weeks (postmenopausal prediabetic)
- Liao 2021 athletic dose-response
- 300-1200mg/day (dose-dependent)
- Bryan Johnson Blueprint
- 1g/day NMN
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about NMN. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
First placebo-controlled human NMN trial: 250 mg/day for 10 weeks improved muscle insulin sensitivity in 25 prediabetic postmenopausal women, with no change in weight, glucose, or lipids
Meta-analysis of eight RCTs (342 adults) found no significant benefit for glucose, insulin, HbA1c, HOMA-IR, or lipids; five of eight trials confirmed an NAD+ rise; more minor adverse events at doses at or above 1000 mg/day
Multicenter dose-ranging RCT (300/600/900 mg) in middle-aged adults: NAD+/NADH rose by day 60, HOMA-IR showed no significant difference vs placebo
Liao 2021 four-arm RCT in 48 amateur runners: 6 weeks of NMN (300/600/1200 mg) with training improved oxygen use at ventilatory thresholds but not VO2max
Liao et al., Journal of the International Society of Sports Nutrition (via PMC)
FDA reversed its NMN exclusion on 29 September 2025, confirming NMN is not excluded from the supplement definition and may be marketed via the new-dietary-ingredient pathway
Detail of the 2025 FDA reversal and the preceding Natural Products Association lawsuit; NMN reinstated as a lawful dietary supplement
November 2022 FDA exclusion of NMN under the drug-preclusion provision because it was authorized for drug investigation (MetroBiotech / MIB-626), after earlier accepting NDI notifications in May 2022
Confirmation of the FDA about-face and that NMN remains a new dietary ingredient requiring notification rather than a grandfathered ingredient
Origin of the field: Yoshino and Imai (2011) showed NMN restores NAD+ and improves glucose tolerance in aged and diabetic mice, plus review of age-related applications
Igarashi 2022 RCT in 20 older men (250 mg/day, 12 weeks): NAD+ rose, gait speed and grip improved, no serious adverse events; and Uthever multicenter tolerability trial context
The studies that matter
Imai NAD+ aging biology foundationalCell 2014, multiple sources
Shin-ichiro Imai at Washington University in St. Louis foundational research characterizing NAD+ decline with aging and NMN biosynthesis pathway biology. Foundational longevity framework that substantially drove subsequent NMN therapeutic positioning.
Mills NMN preclinical longevity mouseCell Metab 2016
Foundational mouse NMN supplementation longevity research demonstrating substantial improvements in age-related physiological decline. Foundational preclinical evidence supporting subsequent human clinical research investment.
Yoshino postmenopausal prediabetic NMN trialScience 2021
Foundational human clinical trial in postmenopausal prediabetic women (250mg/day NMN x 10 weeks) demonstrating substantial improvements in muscle insulin sensitivity. Foundational human translation evidence supporting substantial commercial market expansion.
Liao NMN exercise capacity trialSci Adv 2021
Chinese RCT of NMN (300mg, 600mg, 1200mg/day x 6 weeks) in amateur runners demonstrating substantial dose-dependent improvements in aerobic capacity. Foundational athletic performance evidence supporting substantial commercial market expansion.
Irie NMN safety pharmacokinetic JapaneseEndocr J 2020
Foundational Japanese NMN safety and pharmacokinetic characterization. Substantial Japanese clinical research investment in NMN positioning.
Igarashi NMN metabolomic comprehensiveNature 2022 (preliminary)
Comprehensive metabolomic characterization of NMN supplementation effects in older adults. Substantial mechanism-translation framework expansion supporting broader clinical positioning.
Yamane healthy adults RCTCell Rep Med 2023
Japanese RCT of NMN (250mg/day x 12 weeks) in healthy older adults demonstrating modest improvements in physical performance and metabolic markers. Foundational healthy adult intervention evidence.
Trammell NR pharmacokinetic foundationalNat Commun 2016
Charles Brenner foundational NR pharmacokinetic characterization providing substantial framework for NAD+ precursor supplementation. Substantial mechanism evidence for NR pathway distinct from NMN pathway.
Conze NR clinical NAD+ elevationSci Rep 2019
Demonstrated NR supplementation substantially elevates blood NAD+ levels in humans. Foundational NAD+ precursor clinical translation evidence supporting broader category development.
Brakedal NR Parkinson's diseaseCell Metab 2022
NADPARK trial of NR in Parkinson's disease, substantial NAD+ replenishment evidence supporting potential neurodegenerative applications. Continued NAD+ precursor clinical research expansion.
Reiten NR healthy adultsNutrients 2022
NR supplementation in healthy adults demonstrating modest improvements in mitochondrial function markers. Continued NAD+ precursor framework characterization.
MetroBiotech MIB-626 pharmaceutical NMN developmentMetroBiotech 2021-2024
Substantial pharmaceutical NMN clinical development by MetroBiotech (David Sinclair commercial association), Phase 1, Phase 2 trials investigating pharmaceutical NMN positioning. The substantial pharmaceutical positioning substantially relates to the FDA regulatory complexity affecting NMN supplement category.
FDA NMN letter to Inner Mongolia KingdomwayFDA 2022
Foundational October 2022 FDA letter indicating NMN had been "authorized for investigation as a new drug" prior to substantial supplement marketing under DSHEA, substantially excluding NMN from dietary supplement category under DSHEA Section 201(ff)(3)(B). Substantial M-05 Regulatory whiplash foundational event.